Spevigo — Medica

Initial criteria

• Patient is age ≥ 12 years
• Patient weighs ≥ 40 kilograms
• Patient has history of at least two generalized pustular psoriasis flares of moderate-to-severe intensity in the past
• Patient has a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score of 0 or 1
• Patient meets ONE of the following: (a) Patient has had a 4‑month trial of at least one treatment for generalized pustular psoriasis such as methotrexate, acitretin, cyclosporine, or biologics, and has experienced flaring while on treatment or with dose reduction or discontinuation; OR (b) Patient has tried at least one treatment for generalized pustular psoriasis but was unable to tolerate a 4‑month trial
• Medication is prescribed by or in consultation with a dermatologist

Reauthorization criteria

• Patient has been established on Spevigo subcutaneous therapy for at least 6 months
• Patient has experienced a beneficial clinical response, defined as improvement from baseline in at least one of the following: reduction of generalized pustular psoriasis flares or improvement in Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score

Approval duration

Initial: 6 months; Reauthorization: 1 year